Corporate Developments at Smith & Nebhew plc: Advancing Surgical Robotics and Energy‑Based Instruments
Smith & Nebhew plc has recently announced two strategic initiatives that underscore its commitment to translating cutting‑edge research into clinically validated solutions. The first development involves a collaborative research centre with Imperial College London, dedicated to surgical robotics for musculoskeletal applications. The second is the launch of the FLOW FLEXTEND COBLATION Wand, an evolution of the company’s established FLOW IQ platform designed to enhance joint‑access procedures. Together, these initiatives illustrate a coordinated effort to integrate academic expertise with commercial delivery, thereby accelerating the adoption of safer, more effective technologies across the orthopaedic and trauma care spectrum.
1. Five‑Year Research Centre for Surgical Robotics
1.1 Partnership Objectives
Smith & Nebhew’s partnership with Imperial College London aims to bridge fundamental advances in computer vision, machine learning, and sensor fusion with real‑world surgical workflows. By co‑hosting researchers and engineers from both institutions, the centre will:
| Focus Area | Key Deliverables | Clinical Impact |
|---|---|---|
| Markerless registration | Development of deep‑learning models that localise anatomical landmarks without pre‑operative imaging | Reduces operative time and radiation exposure |
| Real‑time anatomical guidance | Integration of intra‑operative imaging modalities (e.g., ultrasound, fluoroscopy) into robotic control loops | Enhances precision of bone cuts and implant placement |
| Usability & workflow optimisation | Human‑robot interaction studies and ergonomic assessments | Lowers learning curve for surgeons and improves safety margins |
1.2 Evidence‑Based Design & Safety
The centre will adopt a staged validation pathway that mirrors the regulatory expectations of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Initial preclinical trials will employ cadaveric and animal models to evaluate:
- Accuracy: Target positioning error < 1 mm for osteotomies, benchmarked against gold‑standard navigation systems.
- Reliability: Mean time between failures (MTBF) exceeding 10,000 operative hours in simulated scenarios.
- Safety: Adverse event rates (e.g., unintended tissue injury) below 0.1% in high‑throughput bench tests.
Data collected will feed into the company’s iterative design cycle, ensuring that each prototype iteration meets the stringent safety thresholds required for Investigational Device Exemptions (IDEs) before human trials commence.
1.3 Regulatory Pathway
Given the complexity of robotic systems, the partnership will pursue a dual‑track regulatory strategy:
| Stage | Regulatory Body | Submission Type | Key Considerations |
|---|---|---|---|
| 1 | FDA | 510(k) clearance (if predicate device exists) or De Novo | Demonstrate substantial equivalence or new technology classification |
| 2 | EMA | CE marking under In‑Vitam Device Directive (IVDD) / In‑Vitam Medical Devices Regulation (IVDR) | Compliance with risk management and clinical evaluation directives |
| 3 | Global | Harmonised ISO 14971 risk management and ISO 13485 quality systems | Establish post‑market surveillance and adverse event reporting |
2. FLOW FLEXTEND COBLATION Wand
2.1 Technical Overview
The FLOW FLEXTEND wand builds on the proven FLOW IQ COBLATION platform by adding:
- Adjustable‑Angle Tip: Enables a variable angulation of 0–45°, allowing surgeons to access deep joint recesses without repositioning the instrument.
- Set‑and‑Forget Adjustment: Once the angle is locked, the wand maintains the position automatically, reducing manual adjustments during the procedure.
- Balanced Saline Flow & Energy Delivery: Optimised for consistent tissue ablation while minimizing thermal spread, as demonstrated in prior in‑vitro studies.
2.2 Clinical Evidence
Early intra‑operative reports from a cohort of 25 hip, knee, and shoulder arthroscopies indicate:
| Outcome | Metric | Benchmark |
|---|---|---|
| Capsule disruption | Median capsule thickness retained 82% | 75% with conventional instruments |
| Operative time | Mean reduction 12 minutes | 10 minutes |
| Surgeon satisfaction | Likert scale 4.6/5 | 4.2/5 |
While these findings are preliminary and anecdotal, they align with the safety and efficacy data derived from the company’s 20‑year history with the FLOW IQ system.
2.3 Safety Profile
Key safety metrics for the wand include:
- Thermal Injury Rate: < 0.05% in cadaveric tests, consistent with the 0.02% rate observed for FLOW IQ.
- Device Failure: No incidents of tip breakage or fluid leak in 1,500 cumulative operative hours.
- User Error: Training modules have demonstrated a 30% reduction in procedural errors among novice users.
2.4 Regulatory Status
The wand is currently submitted for FDA 510(k) clearance, using FLOW IQ as a predicate. The company anticipates a clearance decision within 9–12 months, contingent on the submission of comprehensive bench and clinical data. In the EU, a CE mark will be sought under the Medical Devices Regulation (MDR) with a classification of Class IIb, reflecting its semi‑invasive nature.
3. Strategic Implications for Patient Care and Healthcare Systems
- Reduced Invasiveness
- The robotic centre’s focus on markerless registration eliminates the need for additional imaging, potentially reducing peri‑operative radiation and contrast exposure.
- The adjustable‑angle wand allows for more precise joint access, minimizing soft‑tissue disruption and potentially accelerating postoperative recovery.
- Enhanced Efficacy
- Accurate bone cuts and implant placements translate to improved biomechanical outcomes and longer implant longevity, as supported by existing literature on robotic assistance.
- Consistent tissue ablation reduces residual debris, lowering the risk of postoperative arthrofibrosis.
- Cost‑Effectiveness
- Shorter operative times and reduced complication rates can lower overall surgical costs.
- The modular design of the wand (set‑and‑forget feature) may reduce operative time and associated anesthesia costs.
- Scalability & Adoption
- By establishing a robust academic partnership, Smith & Nebhew positions itself to rapidly disseminate innovations across a network of teaching hospitals and high‑volume centres.
- The regulatory pathways planned ensure that both the robotic system and the wand can be introduced into diverse markets with a single clearance pathway.
4. Conclusion
Smith & Nebhew plc’s dual initiatives—academic collaboration on surgical robotics and the launch of the FLOW FLEXTEND COBLATION Wand—represent a systematic approach to integrating rigorous research with market‑ready products. By prioritising safety, efficacy, and clear regulatory pathways, the company is poised to deliver clinically meaningful advances that enhance surgical precision, reduce invasiveness, and ultimately improve patient outcomes across orthopaedic and trauma disciplines.
